SEC Form 4 · accession 0001209191-15-049745

NEUROCRINE BIOSCIENCES INC · NBIX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — See Remarks

Period of report

Jun 1, 2015

Accepted (ET)

Jun 3, 2015 · 5:39 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000914475

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock	Jun 1, 2015	M	23,230	$5.76	A	49,843	D
Common Stock	Jun 1, 2015	M	15,000	$2.59	A	64,843	D
Common Stock^F2	Jun 1, 2015	S	38,230	$42.19	D	26,613	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option^F3	$5.76	Jun 1, 2015	M	23,230	D	—	Aug 25, 2021	Common Stock	23,230	41,770	D
Incentive Stock Option^F4	$2.59	Jun 1, 2015	M	15,000	D	—	May 11, 2017	Common Stock	15,000	15,000	D

F1The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
F2Represents a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.68 to $43.90. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F3The option was granted August 25, 2011 and vested in 36 equal monthly installments beginning September 25, 2011.
F4The option was granted May 11, 2010 and vested in 36 equal monthly installments beginning June 11, 2010.

Chief Business Development Officer